What is Perthera?
Founded in 2012, Perthera has established itself as a critical leader in AI-driven precision oncology. The company provides a sophisticated analytics solution currently deployed across more than 250 cancer treatment centers throughout the United States. By integrating complex patient medical, treatment, and molecular data, Perthera empowers oncologists with actionable insights that facilitate personalized therapy selection. This data-centric approach is designed to optimize patient outcomes, specifically targeting improvements in both overall and progression-free survival rates. As a pioneer in the intersection of artificial intelligence and oncology, Perthera serves as a vital bridge between raw clinical data and evidence-based treatment pathways.
How much funding has Perthera raised?
Perthera has raised a total of $11.5M across 5 funding rounds:
Private Equity
$1.3M
Series A
$8.7M
Private Equity
$750K
Debt
$350K
Debt
$393K
Private Equity (2014): $1.3M, investors not publicly disclosed
Series A (2016): $8.7M led by Pilot Growth
Private Equity (2017): $750K supported by Pilot Growth Equity Partners
Debt (2020): $350K featuring PPP
Debt (2021): $393K backed by PPP
Key Investors in Perthera
Pilot Growth
A growth-oriented investment firm that leverages deep expertise in medical technology and genetic screening to support companies transforming clinical health outcomes.
Pilot Growth Equity Partners
A specialized investment partner focused on scaling innovative healthcare solutions that integrate sophisticated technology with clinical expertise to improve patient care.
PPP
Public-Private Partnership
What's next for Perthera?
With the recent influx of capital, Perthera is well-positioned to accelerate its enterprise-level growth strategy. The company is expected to focus on expanding its reach within the oncology market, potentially enhancing its AI Insights platform to incorporate broader genomic datasets and real-time clinical trial matching. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward deepening its integration with existing hospital information systems and scaling its operational capacity to meet the rising demand for precision medicine. This strategic trajectory suggests a continued emphasis on technological differentiation and the pursuit of long-term clinical efficacy, reinforcing its role as an indispensable partner for healthcare providers navigating the complexities of modern cancer care.
See full Perthera company page
